Loading stock data…
Incyte Corporation (INCY)
$124.40-2.35 (-1.85%)
Pre-Market$125.00+0.60 (+0.48%)· Last close Sep 8
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Incyte Corporation in the Healthcare sector is trading at $124.40 with a market capitalization of $24.6B. Wall Street consensus targets $127.74 (23 analysts), implying a +2.7% move over the next 12 months. The stock is currently near its 52-week high of $132.60, remaining 18.7% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.67B↑ | $1.27B↓ | $1.51B↑ | $1.37B↑ | $1.22B |
| Gross Profit | $1.57B↑ | $1.17B↓ | $1.39B↑ | $1.27B↑ | $1.14B |
| Operating Income | $700.39M↑ | $324.17M↓ | $383.96M↓ | $431.30M↑ | $310.81M |
| Net Income | $585.61M↑ | $303.33M↑ | $299.28M↓ | $424.17M↑ | $405.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycyth...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.48
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
25.41%
Volume
Today's trading volume
1.28M
Recent News
2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks
In a recent interview on CNBC’s Halftime Report, Josh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (NASDAQ: INCY) and Biogen (NASDAQ: BIIB) as two of his “Best Stocks in the Market.” Brown said he wanted to focus on stocks that had “nothing to do” with the AI and data-center spending theme. “We wanted to […]
Incyte (INCY) Just Moved, So What Is Drawing Attention Now?
Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...
Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734
Incyte (NasdaqGS: INCY) is drawing attention as its KRAS G12D inhibitor '734 heads into new data presentations at ESMO, focused on pancreatic ductal adenocarcinoma. The upcoming ESMO readout is expected to support ongoing Phase 3 trials of '734 in pancreatic cancer, a disease area with high unmet medical need. Interest is heightened after a competitor recently received FDA approval for a therapy targeting a similar pathway in oncology. This spotlight on Incyte shows how much investor...